Brief: Fate Therapeutics Highlights Positive Durability Of Response Data From FT516 Phase 1 Study For B-Cell Lymphoma
13/12/2021 14:51
Dec 13 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS HIGHLIGHTS POSITIVE DURABILITY OF RESPONSE DATA FROM
FT516
PHASE 1 STUDY FOR B-CELL LYMPHOMA AND ANNOUNCES FDA REGENERATIVE MEDICINE
ADVANCED THERAPY DESIGNATION GRANTED TO FT516 FOR RELAPSED / REFRACTORY DLBCL
Source text for Eikon: ID:nGNX9q8nGf
Further company coverage: FATE.O
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview